Blood Cell JAKtivation Aggravates Cerebral Venous Thrombosis

Overview

Journal Blood Adv

Specialty Hematology

Date 2024 Jun 25

PMID 38916898

Authors

Brandi Reeves

Affiliations

Soon will be listed here.

References

Orion D, Itsekson-Hayosh Z, Peretz S, Mendel R, Yaniv G, Attia M . Janus Kinase-2 V617F Mutation and Antiphospholipid Syndrome in Cerebral Sinus Venous Thrombosis: Natural History and Retrospective Bicenter Analysis. Front Neurol. 2022; 13:783795. PMC: 9046649. DOI: 10.3389/fneur.2022.783795. View

Reeves B, Kim S, Song J, Wilson K, Henderson M, Key N . Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients. Am J Hematol. 2021; 97(2):E37-E40. DOI: 10.1002/ajh.26402. View

Salet D, Bekkering S, Middeldorp S, van den Hoogen L . Targeting thromboinflammation in antiphospholipid syndrome. J Thromb Haemost. 2023; 21(4):744-757. DOI: 10.1016/j.jtha.2022.12.002. View

Noubouossie D, Reeves B, Strahl B, Key N . Neutrophils: back in the thrombosis spotlight. Blood. 2019; 133(20):2186-2197. PMC: 7218731. DOI: 10.1182/blood-2018-10-862243. View

Nagai M, Yilmaz C, Kirchhofer D, Esmon C, Mackman N, Granger D . Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis. Neurosurgery. 2010; 66(3):560-5. PMC: 3089420. DOI: 10.1227/01.NEU.0000365745.49583.FD. View

Gangat N, Guglielmelli P, Betti S, Farrukh F, Carobbio A, Barbui T . Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. Am J Hematol. 2021; 96(12):1580-1586. PMC: 9293093. DOI: 10.1002/ajh.26336. View

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D . Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2012; 368(1):22-33. DOI: 10.1056/NEJMoa1208500. View

Stein B, Williams D, Wang N, Rogers O, Isaacs M, Pemmaraju N . Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010; 95(7):1090-7. PMC: 2895032. DOI: 10.3324/haematol.2009.014407. View

Bhattacharya R, Zekavat S, Haessler J, Fornage M, Raffield L, Uddin M . Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. Stroke. 2021; 53(3):788-797. PMC: 8885769. DOI: 10.1161/STROKEAHA.121.037388. View

10.

Lamrani L, Lacout C, Ollivier V, Denis C, Gardiner E, Ho Tin Noe B . Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood. 2014; 124(7):1136-45. PMC: 4133486. DOI: 10.1182/blood-2013-10-530832. View

11.

Edelmann B, Gupta N, Schnoeder T, Oelschlegel A, Shahzad K, Goldschmidt J . JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J Clin Invest. 2018; 128(10):4359-4371. PMC: 6159978. DOI: 10.1172/JCI90312. View

12.

Moliterno A, Williams D, Rogers O, Isaacs M, Spivak J . Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008; 36(11):1480-6. PMC: 2600434. DOI: 10.1016/j.exphem.2008.05.006. View

13.

Bourrienne M, Le Cam Duchez V, Faille D, Farkh C, Solo Nomenjanahary M, Gay J . Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis. Blood Adv. 2024; 8(12):3330-3343. PMC: 11258627. DOI: 10.1182/bloodadvances.2023011692. View

14.

Buka R, Montague S, Moran L, Martin E, Slater A, Watson S . PF4 activates the c-Mpl-Jak2 pathway in platelets. Blood. 2023; 143(1):64-69. PMC: 10862235. DOI: 10.1182/blood.2023020872. View

15.

Michiels J, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet H . The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 2006; 32(6):589-604. DOI: 10.1055/s-2006-949664. View

16.

Gangaraju R, Song J, Kim S, Tashi T, Reeves B, Sundar K . Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv. 2020; 4(6):1115-1130. PMC: 7094018. DOI: 10.1182/bloodadvances.2019001379. View

17.

Moliterno A, Ginzburg Y, Hoffman R . Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood. 2020; 137(9):1145-1153. PMC: 8215376. DOI: 10.1182/blood.2020008043. View

18.

Jaiswal S, Natarajan P, Silver A, Gibson C, Bick A, Shvartz E . Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017; 377(2):111-121. PMC: 6717509. DOI: 10.1056/NEJMoa1701719. View

19.

Guy A, Helzy K, Mansier O, Bordet J, Riviere E, Fiore M . Platelet function studies in myeloproliferative neoplasms patients with or mutation. Res Pract Thromb Haemost. 2023; 7(2):100060. PMC: 9992751. DOI: 10.1016/j.rpth.2023.100060. View

20.

Moliterno A, Kaizer H, Reeves B . JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood. 2023; 141(16):1934-1942. PMC: 10163319. DOI: 10.1182/blood.2022017697. View